MX375965B - Genes ospa quimericos, proteinas, y metodos para usar los mismos. - Google Patents
Genes ospa quimericos, proteinas, y metodos para usar los mismos.Info
- Publication number
- MX375965B MX375965B MX2017006896A MX2017006896A MX375965B MX 375965 B MX375965 B MX 375965B MX 2017006896 A MX2017006896 A MX 2017006896A MX 2017006896 A MX2017006896 A MX 2017006896A MX 375965 B MX375965 B MX 375965B
- Authority
- MX
- Mexico
- Prior art keywords
- chimeric ospa
- chimeric
- proteins
- methods
- same
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 101001086191 Borrelia burgdorferi Outer surface protein A Proteins 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108700006640 OspA Proteins 0.000 abstract 6
- 208000016604 Lyme disease Diseases 0.000 abstract 3
- 241000589968 Borrelia Species 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 229940042470 lyme disease vaccine Drugs 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6018—Lipids, e.g. in lipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33490110P | 2010-05-14 | 2010-05-14 | |
| PCT/US2011/036525 WO2011143617A1 (en) | 2010-05-14 | 2011-05-13 | Chimeric ospa genes, proteins, and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX375965B true MX375965B (es) | 2025-03-07 |
Family
ID=44121257
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017006896A MX375965B (es) | 2010-05-14 | 2011-05-13 | Genes ospa quimericos, proteinas, y metodos para usar los mismos. |
| MX2012013264A MX340739B (es) | 2010-05-14 | 2011-05-13 | Quimeras ospa y su uso en vacunas. |
| MX2012013261A MX348113B (es) | 2010-05-14 | 2011-05-13 | Genes ospa quimericos, proteinas, y metodos para usar los mismos. |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012013264A MX340739B (es) | 2010-05-14 | 2011-05-13 | Quimeras ospa y su uso en vacunas. |
| MX2012013261A MX348113B (es) | 2010-05-14 | 2011-05-13 | Genes ospa quimericos, proteinas, y metodos para usar los mismos. |
Country Status (13)
| Country | Link |
|---|---|
| US (6) | US8623376B2 (cg-RX-API-DMAC7.html) |
| EP (4) | EP2569008B1 (cg-RX-API-DMAC7.html) |
| JP (6) | JP6030052B2 (cg-RX-API-DMAC7.html) |
| KR (7) | KR102222869B1 (cg-RX-API-DMAC7.html) |
| CN (3) | CN107641151B (cg-RX-API-DMAC7.html) |
| AU (2) | AU2011252844B2 (cg-RX-API-DMAC7.html) |
| BR (2) | BR112012027315B1 (cg-RX-API-DMAC7.html) |
| CA (2) | CA2799181C (cg-RX-API-DMAC7.html) |
| MX (3) | MX375965B (cg-RX-API-DMAC7.html) |
| PL (2) | PL2569009T3 (cg-RX-API-DMAC7.html) |
| RU (2) | RU2636455C2 (cg-RX-API-DMAC7.html) |
| SI (2) | SI2569008T1 (cg-RX-API-DMAC7.html) |
| WO (2) | WO2011143617A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2569008B1 (en) * | 2010-05-14 | 2019-12-25 | Baxalta Incorporated | Ospa chimeras and use thereof in vaccines |
| US20120123924A1 (en) | 2010-10-20 | 2012-05-17 | Mark Rose | Virtual currency configuration apparatuses, methods and systems |
| US10438176B2 (en) | 2011-07-17 | 2019-10-08 | Visa International Service Association | Multiple merchant payment processor platform apparatuses, methods and systems |
| US10318941B2 (en) | 2011-12-13 | 2019-06-11 | Visa International Service Association | Payment platform interface widget generation apparatuses, methods and systems |
| US10096022B2 (en) * | 2011-12-13 | 2018-10-09 | Visa International Service Association | Dynamic widget generator apparatuses, methods and systems |
| US8986704B2 (en) * | 2012-07-06 | 2015-03-24 | Valneva Austria Gmbh | Mutant fragments of OspA and methods and uses relating thereto |
| CN104640563A (zh) * | 2012-07-27 | 2015-05-20 | 巴克斯特国际公司 | 包含嵌合的ospa分子的组合物及其使用方法 |
| PL223175B1 (pl) | 2012-10-22 | 2016-10-31 | Inst Chemii Bioorganicznej Polskiej Akademii Nauk | Szczepionka przeciw boreliozie, konstrukt genetyczny, rekombinowane białko, sposób otrzymywania konstruktu genetycznego, sposób otrzymywania szczepionki, sposób otrzymywania rekombinowanych białek, zastosowanie rekombinowanych białek do wytwarzania szczepionki przeciwko boreliozie |
| MX371272B (es) * | 2013-03-15 | 2020-01-22 | Univ California | El péptido mots3 derivado de mitocondrias regula el metabolismo y la supervivencia celular. |
| WO2015041710A1 (en) * | 2013-09-23 | 2015-03-26 | Ventria Bioscience, Inc. | Ospa fusion protein for vaccination against lyme disease |
| BR112016015678B1 (pt) * | 2014-01-09 | 2024-02-06 | Valneva Austria Gmbh | Polipeptídeo compreendendo um fragmento de ospa de c-terminal híbrido, seu processo de produção, seu uso, ácido nucleico, vetor, célula hospedeira, composição farmacêutica |
| CZ2014320A3 (cs) * | 2014-05-09 | 2015-11-18 | VÝZKUMNÝ ÚSTAV VETERINÁRNÍHO LÉKAŘSTVÍ, v.v.i. | Polyepitopový antigen, vakcinační konstrukt a vakcína pro prevenci lymeské boreliózy |
| CA2958018A1 (en) | 2014-08-11 | 2016-02-18 | University Of Massachusetts | Anti-ospa antibodies and methods of use |
| US11216468B2 (en) | 2015-02-08 | 2022-01-04 | Visa International Service Association | Converged merchant processing apparatuses, methods and systems |
| US10735952B2 (en) * | 2015-08-14 | 2020-08-04 | Telefonaktiebolaget Lm Ericsson (Publ) | Node and method for managing a packet data network connection |
| KR20210117359A (ko) * | 2016-11-07 | 2021-09-28 | 더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지 | 라임병에 사용하기 위한 dna 항체 작제물 |
| WO2018189372A1 (en) * | 2017-04-13 | 2018-10-18 | Valneva Austria Gmbh | Multivalent ospa polypeptides and methods and uses relating thereto |
| CN112584858A (zh) * | 2018-04-03 | 2021-03-30 | 赛诺菲 | 抗原性ospa多肽 |
| WO2019195291A1 (en) | 2018-04-03 | 2019-10-10 | Sanofi | Antigenic respiratory syncytial virus polypeptides |
| EP3773698A1 (en) | 2018-04-03 | 2021-02-17 | Sanofi | Ferritin proteins |
| EP3773708A2 (en) | 2018-04-03 | 2021-02-17 | Sanofi | Antigenic epstein barr virus polypeptides |
| CN110483624B (zh) * | 2019-08-22 | 2021-02-09 | 中国疾病预防控制中心传染病预防控制所 | 伽氏疏螺旋体OspA蛋白C端肽段及其应用 |
| CN111196842A (zh) * | 2020-01-09 | 2020-05-26 | 济南大学 | 一种外膜转运通道蛋白的非跨膜结构域的表达纯化方法 |
| CA3174666A1 (en) | 2020-04-09 | 2021-10-14 | Robert Schlegl | Improved methods of producing a lipidated protein |
| BR112022020438A2 (pt) * | 2020-04-09 | 2022-11-29 | Valneva Austria Gmbh | Composições compreendendo três proteínas de fusão ospa para uso médico |
| US12228578B2 (en) | 2020-12-17 | 2025-02-18 | Idexx Laboratories, Inc. | Rocky mountain spotted fever detection and treatment |
| WO2022261050A1 (en) * | 2021-06-07 | 2022-12-15 | The University Of Massachusetts | Apparatus and method for continuous production of rna |
| CA3244889A1 (en) | 2022-03-08 | 2023-09-14 | Equashield Medical Ltd | FLUID TRANSFER STATION IN A ROBOTIC PHARMACEUTICAL PREPARATION SYSTEM |
| WO2025015042A1 (en) | 2023-07-10 | 2025-01-16 | Dynavax Technologies Corporation | Lyme disease vaccines comprising an adjuvant and a borrelia outer surface protein a antigen |
| WO2025015077A1 (en) | 2023-07-10 | 2025-01-16 | Dynavax Technologies Corporation | Lyme disease vaccines comprising an adjuvant and borrelia outer surface protein a and c antigens |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK590288D0 (da) * | 1988-10-24 | 1988-10-24 | Symbicom Ab | Kemiske forbindelser |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| SE8205892D0 (sv) | 1982-10-18 | 1982-10-18 | Bror Morein | Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
| SE8405493D0 (sv) | 1984-11-01 | 1984-11-01 | Bror Morein | Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel |
| US4877612A (en) | 1985-05-20 | 1989-10-31 | Frank M. Berger | Immunological adjuvant and process for preparing the same, pharmaceutical compositions, and process |
| DE3521994A1 (de) | 1985-06-20 | 1987-01-02 | Bayer Ag | N-(2-aminoacylamido-2-desoxy-hexosyl)-amide-, -carbamate und -harnstoffe, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln |
| DK166762B1 (da) | 1986-01-14 | 1993-07-12 | Nederlanden Staat | Fremgangsmaade til fremstilling af immunogenkomplekser og farmaceutisk sammensaetning indeholdende saadanne komplekser |
| US4806352A (en) | 1986-04-15 | 1989-02-21 | Ribi Immunochem Research Inc. | Immunological lipid emulsion adjuvant |
| US4830885A (en) | 1987-06-08 | 1989-05-16 | Allied-Signal Inc. | Chlorine-resistant semipermeable membranes |
| US6143872A (en) | 1988-10-24 | 2000-11-07 | Symbicom Aktiebolag | Borrelia burdorferi Osp A and B proteins and immunogenic peptides |
| US5777095A (en) | 1988-10-24 | 1998-07-07 | Symbicom Aktiebolag | Osp A and B Sequence of Borrelia burgdonferi strains ACA1 and IP90 |
| US7094391B1 (en) | 1988-10-24 | 2006-08-22 | The University Of Texas System | Compositions and methods for administering Borrelia burgdorferi antigens |
| WO1990006952A1 (fr) | 1988-12-22 | 1990-06-28 | Kirin-Amgen, Inc. | Facteur de stimulation de colonies de granulocytes modifies chimiquement |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| SG122738A1 (en) * | 1990-06-15 | 2006-06-29 | Univ Yale | Compositions and methods for the prevention and diagnosis of lyme disease |
| US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| ATE168132T1 (de) | 1991-02-15 | 1998-07-15 | Uab Research Foundation | Strukturgen von pneumokokken-protein |
| US6676942B1 (en) | 1991-08-15 | 2004-01-13 | Smithkline Beecham Biologicals (S.A.) | Osp a proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines |
| DK0598816T3 (da) | 1991-08-15 | 1999-11-22 | Deutsches Krebsforsch | Osp A-proteiner fra Borrelia Burgdorferi-undergrupper, hvilke proteiner koder for gener og vacciner |
| US5234784A (en) | 1992-04-01 | 1993-08-10 | Eastman Kodak Company | Method of making a projection viewable transparency comprising an electrostatographic toner image |
| US7008625B2 (en) | 1993-11-01 | 2006-03-07 | Research Foundation Of The State University Of New York | Recombinant constructs of Borrelia burgdorferi |
| ES2219657T3 (es) | 1993-11-01 | 2004-12-01 | Brookhaven Science Associates | Proteinas quimericas que comprenden polipeptidos de borrelia: usos para las mismas. |
| US6248562B1 (en) | 1993-11-01 | 2001-06-19 | Research Foundation State University Of New York | Chimeric proteins comprising borrelia polypeptides and uses therefor |
| ATE225668T1 (de) | 1996-02-12 | 2002-10-15 | Cobra Therapeutics Ltd | Neue methode zur impfung sowie impfstoffe dafür, die eine epitopkodierende nukleinsäure und ein epitopenthaltende peptid beinhalten |
| US6368603B1 (en) * | 1997-03-05 | 2002-04-09 | Merial Limited | Lyme combination compositions and uses |
| US6660274B2 (en) * | 1997-06-30 | 2003-12-09 | The Administrators Of The Tulane Educational Fund | Surface antigens and proteins useful in compositions for the diagnosis and prevention of lyme disease |
| US6342220B1 (en) | 1997-08-25 | 2002-01-29 | Genentech, Inc. | Agonist antibodies |
| GB9726555D0 (en) | 1997-12-16 | 1998-02-11 | Smithkline Beecham Plc | Vaccine |
| US6541011B2 (en) * | 1998-02-11 | 2003-04-01 | Maxygen, Inc. | Antigen library immunization |
| GB9811219D0 (en) | 1998-05-26 | 1998-07-22 | Smithkline Beecham Biolog | Novel process |
| AU2001281145A1 (en) * | 2000-08-18 | 2002-03-04 | Brookhaven Sciences Associates, Llc | Recombinant constructs of borrelia burgdorferi |
| PT1311540E (pt) | 2000-08-18 | 2008-03-20 | Univ New York State Res Found | Ospa de borrelia burgdorferi modificada |
| EP1939294A1 (en) * | 2000-08-18 | 2008-07-02 | Research Foundation Of State University Of New York | Recombinant constructs of borrelia burgdorferi |
| RU2385323C2 (ru) | 2003-04-02 | 2010-03-27 | ДЗЕ ГАВЕРМЕНТ ОФ ДЗЕ ЮНАЙТЕД СТЕЙТС ОФ АМЕРИКА Эз репрезентед бай ДЗЕ СЕКРЕТЭРИ, ДЕПАРТМЕНТ ОФ ХЕЛТ ЭНД ХЬЮМЭН СЕРВИСИЗ | Холестеринсодержащие соединения и их применение в качестве иммуногенов против borrelia burgdorferi |
| KR20060019515A (ko) * | 2003-04-16 | 2006-03-03 | 와이어쓰 홀딩스 코포레이션 | 수막구균 질환의 예방 및 치료용 신규 면역원성 조성물 |
| DE602005020913D1 (de) * | 2004-03-24 | 2010-06-10 | Merck Sharp & Dohme | Optimierte expression von hpv-52-l1 in hefe |
| EP1768688A4 (en) | 2004-07-02 | 2009-09-30 | Raymond J Dattwyler | ORAL BORRELIOSE VACCINE |
| GB0417494D0 (en) | 2004-08-05 | 2004-09-08 | Glaxosmithkline Biolog Sa | Vaccine |
| EP1957520A4 (en) | 2005-11-29 | 2009-05-27 | Univ Virginia Commonwealth | POLYVALENTIC CHIMERIC OSPC VACCINOGEN AND DIAGNOSTIC ANTIGEN |
| RU2008126239A (ru) * | 2005-11-29 | 2010-01-10 | Вирджиния Коммонвелт Юниверсити (Us) | Поливалентный химерный вакциноген и диагностический антиген ospc |
| CA2661224A1 (en) | 2006-09-15 | 2008-03-20 | Intercell Ag | Borrelia antigens |
| ATE496935T1 (de) | 2007-02-22 | 2011-02-15 | Baxter Int | Verfahren zur aufreinigung hydrophober proteine |
| HRP20151122T1 (hr) * | 2007-06-26 | 2015-11-20 | Glaxosmithkline Biologicals S.A. | Cjepivo koje sadrži konjugate polisaharida iz kapsule bakterije streptococcus pneumoniae |
| WO2009099716A1 (en) * | 2008-01-11 | 2009-08-13 | Vgx Pharmaceuticals, Inc. | Novel vaccines against multiple subtypes of dengue virus |
| US20110105355A1 (en) | 2008-04-22 | 2011-05-05 | Research Foundation Of State University Of New York | Borrelia burgdorferi cell envelope protein array |
| WO2009135118A2 (en) | 2008-05-02 | 2009-11-05 | Virginia Commonwealth University | Lyme disease vaccine |
| EP2569008B1 (en) | 2010-05-14 | 2019-12-25 | Baxalta Incorporated | Ospa chimeras and use thereof in vaccines |
| CN104640563A (zh) * | 2012-07-27 | 2015-05-20 | 巴克斯特国际公司 | 包含嵌合的ospa分子的组合物及其使用方法 |
-
2011
- 2011-05-13 EP EP11720967.6A patent/EP2569008B1/en active Active
- 2011-05-13 CN CN201710853809.2A patent/CN107641151B/zh active Active
- 2011-05-13 KR KR1020207005820A patent/KR102222869B1/ko not_active Expired - Fee Related
- 2011-05-13 PL PL11722243T patent/PL2569009T3/pl unknown
- 2011-05-13 BR BR112012027315-9A patent/BR112012027315B1/pt active IP Right Grant
- 2011-05-13 KR KR1020187019612A patent/KR20180082633A/ko not_active Ceased
- 2011-05-13 PL PL11720967T patent/PL2569008T3/pl unknown
- 2011-05-13 RU RU2012153972A patent/RU2636455C2/ru active
- 2011-05-13 MX MX2017006896A patent/MX375965B/es unknown
- 2011-05-13 WO PCT/US2011/036525 patent/WO2011143617A1/en not_active Ceased
- 2011-05-13 WO PCT/US2011/036533 patent/WO2011143623A1/en not_active Ceased
- 2011-05-13 MX MX2012013264A patent/MX340739B/es active IP Right Grant
- 2011-05-13 AU AU2011252844A patent/AU2011252844B2/en not_active Ceased
- 2011-05-13 EP EP11722243.0A patent/EP2569009B1/en active Active
- 2011-05-13 KR KR1020127032561A patent/KR20130062954A/ko not_active Ceased
- 2011-05-13 CN CN201180033682.0A patent/CN103118701B/zh active Active
- 2011-05-13 JP JP2013510352A patent/JP6030052B2/ja not_active Expired - Fee Related
- 2011-05-13 US US13/107,796 patent/US8623376B2/en active Active
- 2011-05-13 BR BR112012029058-4A patent/BR112012029058B1/pt active IP Right Grant
- 2011-05-13 CN CN201180033687.3A patent/CN103108652B/zh active Active
- 2011-05-13 KR KR1020197006820A patent/KR102130584B1/ko active Active
- 2011-05-13 CA CA2799181A patent/CA2799181C/en active Active
- 2011-05-13 CA CA2798331A patent/CA2798331C/en active Active
- 2011-05-13 SI SI201131835T patent/SI2569008T1/sl unknown
- 2011-05-13 RU RU2012153752/10A patent/RU2583289C2/ru active
- 2011-05-13 MX MX2012013261A patent/MX348113B/es active IP Right Grant
- 2011-05-13 AU AU2011252850A patent/AU2011252850B2/en not_active Ceased
- 2011-05-13 KR KR1020127032560A patent/KR20130133120A/ko not_active Ceased
- 2011-05-13 EP EP19217974.5A patent/EP3705133B1/en active Active
- 2011-05-13 SI SI201131829T patent/SI2569009T1/sl unknown
- 2011-05-13 US US13/107,787 patent/US8623375B2/en active Active
- 2011-05-13 KR KR1020207018904A patent/KR102230562B1/ko active Active
- 2011-05-13 KR KR1020187007814A patent/KR102085465B1/ko not_active Expired - Fee Related
- 2011-05-13 JP JP2013510354A patent/JP6227407B2/ja not_active Expired - Fee Related
- 2011-05-13 EP EP19201651.7A patent/EP3650041A1/en not_active Withdrawn
-
2013
- 2013-11-12 US US14/078,390 patent/US9303073B2/en active Active
- 2013-11-12 US US14/078,367 patent/US9334311B2/en active Active
-
2016
- 2016-02-22 US US15/049,438 patent/US9895434B2/en active Active
- 2016-06-27 JP JP2016126608A patent/JP2016168057A/ja not_active Withdrawn
- 2016-06-27 JP JP2016126631A patent/JP2016171816A/ja active Pending
-
2018
- 2018-01-19 US US15/875,479 patent/US11305000B2/en active Active
- 2018-07-09 JP JP2018129896A patent/JP2018150386A/ja not_active Withdrawn
-
2020
- 2020-08-11 JP JP2020135857A patent/JP6965417B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX375965B (es) | Genes ospa quimericos, proteinas, y metodos para usar los mismos. | |
| MX395525B (es) | Composiciones inmunogenicas para usar en vacunas neumococicas. | |
| WO2014018274A8 (en) | Compositions comprising chimeric ospa molecules and methods of use thereof | |
| BR112013018416A2 (pt) | dispositivos médicos infláveis | |
| BR112016003358A2 (pt) | método para aumentar a expressão de proteínas codificadas por rna | |
| CY1122483T1 (el) | Λυοφιλοποιημενες παρασκευες μελφαλανης φλουφεναμιδης | |
| MX2013002207A (es) | Vacunas contra el cancer cerebral basadas en peptido alfa 2 del receptor de interleucina 13. | |
| BR112015022096A8 (pt) | compostos moduladores de canal de sódio, composição que os compreende e uso dos mesmos | |
| CL2015002941A1 (es) | Usos terapéuticos de empaglifozina | |
| BR112015001313A2 (pt) | composições de vacina | |
| BR112014013140A2 (pt) | cosmética de prótese | |
| IL222651B (en) | Raav-guanylate cyclase compositions and methods for treating leber's congenital amaurosis-1 (lca1) | |
| BR112013020586A2 (pt) | Uso de células derivadas de tecido do cordão umbilical | |
| PH12016500296A1 (en) | Sodium channel modulators for the treatment of pain and diabetes | |
| MX2010011561A (es) | Remineralizacion del tejido calcificado. | |
| UA114286C2 (uk) | Спосіб лікування staphylococcus aureus | |
| MX346596B (es) | Oligodesoxinucleotidos inmunoestimuladores. | |
| CL2011002766A1 (es) | Compuestos derivados de carboxamida, inhibidores de calpaina; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades neurodegenerativas, alzahimer, dolor, entre otras. | |
| BR112015013125A2 (pt) | tratamento de lesões orais usando composições de matrix placentário extracelular | |
| MX381102B (es) | Benralizumab para usarse en el tratamiento de asma incrementando el volumen espiratorio forzado. | |
| EA201390417A1 (ru) | Антидиабетические твердые фармацевтические композиции | |
| AR090726A1 (es) | Vacunas y procedimientos para tratar la enfermedad de lyme en perros | |
| MY170725A (en) | Dengue-virus serotype neutralizing antibodies | |
| CY1111361T1 (el) | Νεα προσδεματα συναγωνιστες των υποδοχεων rar, χρηση στην ανθρωπινη ιατρικη καθως και στην κοσμετολογια | |
| EA201590732A1 (ru) | Диспергируемая таблетка |